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Introduction
Cathepsin D, which is an aspartyl protease and direct-
ly activates other cathepsin,  plays an important role in
the tumour invasion and metastasis and is a subject of
numerous reviews [1-3]. Cathepsin D is one of the
main proteolytic enzymes contributing to the develop-
ment of cancer [4].
In our review we would like to present the current
state of knowledge regarding the meaning of the cys-
teine peptidases in breast and genital cancer prognosis.
Cysteine proteinase inhibitors
Cysteine proteinases are ultimately regulated by
endogenous cysteine proteinase inhibitors. These
inhibitors have been subdivided into three families,
termed stefins, cystatins and kininogens. It is general-
ly assumed that these inhibitors are involved in the
regulation of physiological and pathological processes
caused by cysteine proteinases [5]. Cysteine proteinase
inhibitors of all three families were found in ascitic
fluid from patients with ovarian carcinoma. The high-
est apparent inhibition against cathepsin B was found
in low molecular mass [6]. Kobayashi et al. demon-
strated the presence of the anti-metastatic activity in
the acid extract from human amniotic fluid. In previ-
ous it study was demonstrated that urinary trypsin
inhibitor, which is one of the physiological trypsin
inhibitors, isolated and purified from human urine, is
able to inhibit tumor cell invasion [7].  Structurally
more distant members of the cystatin superfamily have
been reported, such as p21, the product of c-Ha-ras
oncogene, which may be involved in earlier steps of
tumor progression [8]. More recently, p41 a fragment
from the invariant chain of the major histocompatibil-
ity complex (MHC) II, thyroglobulin types I domain
and equinatoxin, an inhibitor from sea anemone, were
discovered, all being cysteine proteinase inhibitors
with no close structural homology to cystatins [9]. The
recent discovery of two new cysteine proteinase
inhibitors highlights the similarity between serine and
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proteinase inhibitors. The two new members of the
serpin family (a family of serine proteinase inhibitors)
appear to process potent inhibitory activity toward
cysteine proteinases, and its ability to inhibit Inter-
leukin 2-converting enzymes (ICE) and block the
apoptotic process. This sepin was subsequently found
to inhibit cathepsin L [10]. 
The mechanism of interaction between 
cysteine proteinase inhibitors and cysteine
proteinases
The cystatins are reversible, tight-binding competitive
inhibitors of cysteine proteinases. However, due to
their extremely tight interactions with certain target
enzymes, it has been difficult to verify, and dissocia-
tion equilibrium constants are difficult to determine
accurately by equilibrium methods. A review of kinet-
ic and structural data has enabled the authors to recon-
sider the definition of substrate binding sites in papain-
like cysteine proteases. The location and definition of
substrate binding sites beyond S3 and S2' are even
more questionable. These results clearly indicate the
differences in the specificity of interaction between the
N-terminal region of cystatin C and cathepsins B, H, L
and S, and that, although cystatin C has evolved to be
a good inhibitor of all the mammalian cysteine pro-
teinases, more specific inhibitors of the individual
enzymes can be engineered [11,12]  
Stopped-flow kinetics showed that the inhibition of
the lysosomal cysteine proteinase, cathepsin B, by its
endogenous inhibitor, cystatin C, occurs by a two-step
mechanism, in which an initial, weak interaction is fol-
lowed by a conformational change. The initial interac-
tion most likely involves binding of the N-terminal
region of the inhibitor to the proteinase. The presence
of this loop, which allows the enzyme to function as an
exopeptidase, thus complicates the inhibition mecha-
nism, rendering cathepsin B much less susceptible
than other cysteine proteinases to inhibition by cys-
tatins. The N-terminal region of human cystatin C has
been shown to be of crucial importance for the inter-
action of the inhibitor with cysteine proteinases. These
results show that bovine cystatin C has 118 residues, in
contrast to 110-112 residues reported previously, and
has an N-terminal region analogous to that of human
cystatin C. This region presumably is of similar impor-
tance for tight binding of target proteinases as a human
proteases [13].
Inhibition of calpain by human kininogen domain 2
requires the correct conformation and combination of
several contact sites, and this suggests that the N-ter-
minus and the first hairpin loop play a major role in
this ensemble. Remarkably, hybrid sc2-KD2 exhibited
5 and 150 times stronger inhibition of actinidin com-
pared to native chicken cystatin and to proteolytically
isolated from human kininogen domain 2, respective-
ly. This indicates an important role of the first hairpin
loop of cystatins in the interaction with actinidin.
Along with the impaired inhibition of cathepsin L,
papain, actinidin, cathepsin B and calpain by the
hybrids sc1/3-KD2, sc2/3-KD2 and sc1/2/3-KD2,
these results support the hypothesis that all three pre-
dicted contact regions of kininogen domain 2 con-
tribute to binding in the active-site clefts of papain-like
enzymes in a finely balanced manner [14].The kinino-
gens thus have the potential for binding two molecules
of cysteine proteinases, the evidence regarding the
binding stiochiometry of the intact molecules was con-
flicting . Recently, both intact LMK and HMK have
been shown by several methods to bind two molecules
of papain, cruzipain and cathepsins, H, L and S, thus
clarifying the dilemma. Moreover, the two binding
sites on HMK and LMK bind proteinase with different
binding rates [15]. The inhibition of endopeptidases
papain, cathepsins S and L and cruzipain by animal
cystatins are extremely tight and ripped whereas the
inhibition of exopeptidases cathepsins B and H  is con-
siderably weaker. The active site cleft of known
endopeptidases is free to accommodate the inhibitors,
whereas in the case of exopeptidases the active site
cleft contains additional enzyme residues. In carboxy-
dipeptidase cathepsin B its occluding loop partly occu-
pies the active site cleft and needs to be displaced in
order to accept a cystatin molecule [16]. 
Breast cancer
Cathepsin D was first of  the lysosomal enzymes
proved to be of prognostic significance for survival of
breast cancer patients [17]. Podgorski and Sloane [18]
reported that a group of breast cancer patients with low
cathepsin B levels experienced poor survival. In a
recent study of matched pairs of breast tumors and
control breast tissues, increased activity and protein
levels of cathepsin B proved to be of a better prognos-
tic indicator value than those of cathepsin L, while
cathepsin D increase did not show this [19]. In a lymph
node negative population, cathepsin B protein and
activity were better prognostic indicator for disease-
free survival than in the total patient population. On
the other hand the expression of cathepsin B in gastric
carcinoma is associated with lymph node metastasis
but not with postoperative survival [20], the negative
cathepsin D staining was related with one year survival
in advanced squamous cell carcinoma [21] and cathep-
sin K and cystatin C were not predictors of the survival
in patients with advanced non-small-cell lung cancer
during chemotherapy [22]. In Harcbeck and al. study a
large increase in cathepsins B, L enzymatic activity
was measured relative to their protein concentrations,
indicating highly enhanced activation of cathepsins in
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tumors [19]. The latter may be due either to the
enhanced activation of their precursors and/or to the
downregulation of the endogenous inhibitors. Indeed,
a significant decrease of stefin A level in some, but not
all tumor was observed. Immunohistochemical analy-
sis of stefin A in breast tumors revealed an opposite
relation to survival compared with the studies on activ-
ity and protein level. Munster and Norton [23] found
that risks of death was significantly higher in patients
with positive staining of stefin A in tumors. The
increase in  risk was also significant in lymph node
negative patients. Furthermore, co-expression of stefin
A and p53 were indicative for high-risk patients. In the
recent study it was found that 57 patient out of 1,500
with primary breast carcinoma, both cathepsin B and
cathepsin L levels were found to be effective in pre-
dicting the rate of relapse and the length of survival
after removal of the primary tumor. The levels, meas-
ured in tumor tissue cytosols, were positively correlat-
ed with the number of positive lymph nodes and nega-
tively with the level of the steroid-hormones receptors.
No significant relationship was found between cathep-
sin B and L levels and age, menopausal status of the
patients and size of the primary tumor. The levels of
cathepsin B and L positively correlated with each other
and the relapse-free and overall survival in univariate
analysis. In multivariate regression analysis, corrected
for age, menopausal status, tumor size, the number of
invaded lymph nodes and steroid-hormone receptor
status, cathepsin B and L were found to be significant
independent factors for prediction of the rates of
relapse and death. It was also found that the estrogen-
induced degradation of estrogen-receptor (ER) protein
could be prevented by pretreatment with peptide alde-
hyde inhibitors of proteasome protease whereas
inhibitors of calpain and lysosomal proteases were
ineffective. Inhibition of proteasome activity, main-
tained ER protein at a level equivalent to control cells
not stimulated with estrogens but increased estrogens-
binding activity by 1.75-fold. The comparative prog-
nostic value of Cathepsin D and urokinase plasmino-
gen activator was detected by immunohistochemistry,
in primary breast carcinoma [24]. In node-negative
breast cancer, 70% of the patients were treated by sur-
gery alone and thus there is a necessity of systemic
adjuvant treatment. Histomorphological and tumor
biological prognostic factors may be employed to
assess the patient's risk profile with regard to disease
recurrence and death. Cysteine protease cathepsin L,
serine protease uPA, and the protease inhibitor PAI-1
were determined by ELISA in extracts of primary
tumors of 103 node-negative breast cancer patients and
values assessed by univariate and multivariate analysis
in comparison with traditional prognostic factors
(tumor size, steroid hormone receptor status, grading,
vessel invasion, menopausal status). Combined deter-
mination of PAI-1 and cathepsin L tumor levels low-
risk node-negative breast cancer patients may be iden-
tified. These patients most probably will not benefit
from systemic adjuvant therapy [25]. Proteinases are
attractive targets for drug development in therapeutic
application. The use of novel inhibitors in clinical
practice is dependent not just on their specificity and
effectiveness, but mainly on the knowledge of their
precise role in the mechanisms of the proteolytic sys-
tem in the development of malignant disease [26]. The
lysosomal cysteine protease inhibitor 9-fluorenyl-
methyloxycarbonyl-tyrosylalanyl-diazomethane was
found to inhibit growth of the breast cancer cell lines
SK-Br-3 and MCF-7. The conjugated inhibitor was
delivered and targeted to cathepsin B and an unidenti-
fied protein of Mr 39,000 in the SK-Br-3 cells. The
results in this report show that targeting of cysteine
protease inhibitors can selectively control tumor cell
growth and that targeted cysteine protease inhibitors
could prove valuable in the development of novel anti-
cancer immunotherapies. Bowman-Birk inhibitor
(BBI) is a soybean-derived anticarcinogenic protease
inhibitor previously shown to potentate cisplatin-
induced cytoxicity in human lung and ovarian cancer
cells. To further assess the potential of BBI as a sensi-
tizing agent for cancer radiotherapy and chemothera-
py, they evaluated the effects of BBI and a soybean
concentrate enriched in BBI known as BBI concentrate
(BBIC) on clonogenic survival and radiation- or cis-
platin-induced cell killing in human breast carcinoma
cells, head and neck, carcinoma cells, human cervical
carcinoma cells, and nontumorigenic human epithelial
cells. These results suggest that BBIC could be a use-
ful agent for the potentiation of radiation- and cis-
platin-mediated cancer treatment without significant
adverse effects on surrounding normal tissues [27].
Urinary trypsin inhibitor (UTI) which is one of the
physiological trypsin inhibitors, isolated and purified
from human urine is able to inhibit lung metastasis of
muse Lewis lung carcinoma (3LL) cells in experimen-
tal and spontaneous metastasis model. The combina-
tion of an anti-metastasis (UTI) with an anti-cancer
drug, etoposide showed a significant reduction in the
formation of lung metastasis, and might provide a ther-
apeutical basis for anti-metastatic therapy [28,29]. 
The present results indicate that release of lysoso-
mal cysteine proteinase from the lysosomal compart-
ments is of little or no importance in the photochemi-
cal inactivation of NHIK 3025 cells when TPPS4 is
used as photosensitizer. All human biological fluids
and tissues investigated showed cysteine proteinase
inhibiting activity, but it is not known whether the
above-mentioned inhibitors account for major part of
this activity; neither it is not known, nor it is known
whether their relative concentrations vary between dif-
ferent biological sources, and if they have the capacity
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to play an important physiological and pathophysio-
logical roles as cysteine proteinase inhibitors [30],
reported that human amniotic fluid has anti-metastasis
factor of molecular mass about 60-70 kDa identified as
trypsin proteinase inhibitor. Recent findings on the
role of cathepsins B, H, and L and their endogenous
inhibitors in breast carcinomas as biological prognos-
tic markers in human cancers were reviewed. We
observed that cat B and procat B activities were ele-
vated 45-fold and 24-fold respectively in tumor
patients with ovarian carcinomas as compared with
controls tissue. An imbalance between cysteine pro-
teinase and endogenous cysteine proteinase inhibitors in
ovarian and breast carcinomas was possibly due to
impaired inhibition of proteinases. Alternatively, less
effective inhibition by the endogenous inhibitors in
tumors may be responsible for the activation of cysteine
cathepsins. Secreted procath B is able to bind extracel-
lular matrix components such as laminin or collegians,
and eventually it is activated extracellulary by cat  D.
Premzl et al. [31] studied the effects of E-64 (CPI)  on
metastasis formation in mice with mammary and ovari-
an tumors. The data suggests that cat B, L, and D seem
to be involved in early steps of the metastasis process
rather than in the haematogenous spread of tumor cells,
and other pharmacological activities which may account
for the discrepant effects of E-64 on experimental and
spontaneous metastasis cannot be ruled out. The ability
to block invasive tumor cells in vitro with cysteine pro-
teinase inhibitors supports a role for active cysteine pro-
teinases in the invasion of some tumor cells. Bervar et
al. [32] have recently shown that cystatin A was associ-
ated with negative BcI-2 staining, but there was no sta-
tistically significant association between axially lymph
node status and p53 immunostaining in breast cancer,
showing that a novel Immunohistochemical staining
pattern involving CPI cystatin A in breast tumors was
associated with poor histological differentiation.
Proteinase inhibitors became targets for drug develop-
ment in anti-tumor therapy. To our knowledge, this is
the first report on in vivo application of photodynamic
therapy together with cysteine proteinase inhibitor [33]. 
Clinical relevance of cysteine proteinases 
in genital cancer
Human ovarian cancer is characterised by its tendency
to extend over the peritoneal surface of the abdominal
cavity, resulting into a wide-spread disease. At its ter-
minal stages, multiple metastatic foci appear in distant
organs, possibly with the involvement of proteolytic
enzymes. Ovarian cancer cell lines express detectable
and reproducible levels of surface urokinase-type plas-
minogen activator and cathepsin B [34]. A latent, high
molecular mass form of cathepsin B, presumably pro-
cathepsin B, has been shown to accumulate in malig-
nant ascitic fluids, among others from patients with
ovarian cancer [35, 36]. Cathepsin B activity, deter-
mined in serum was suggested as a factor for estimating
the extent and spread of uterine cervical carcinoma [37].
The activity of this enzyme increased both in serum and
in the tumor with the progression of the disease and was
dependent on the clinical stage of cervical carcinoma.
Ovarian carcinomas secrete single-chain urinary-type
plasminogen activator (scuPA) and expression of uPA is
up-regulated relative to normal ovarian epithelium,
leading to an enhanced proteolytic capacity that may
facilitate invasion. Both NTF and scuPA induced a
dose-dependent increase in proliferation, with maximal
stimulation obtained at 10-20 nM. Furthermore, block-
ing the interaction of endogenous uPA with uPAR using
anti-NTF antibodies significantly inhibited prolifera-
tion. Together these datas indicate that, in addition to
enhancing the invasive activity of ovarian carcinoma
cells via increased pericellular proteolysis, uPA also acts
as a mitogen for ovarian carcinoma cells, suggesting a
biochemical mechanism whereby uPA may contribute
to ovarian carcinoma progression by modulating both
cell invasion and proliferation [37]. Furthermore, in the
spontaneous metastasis model, the hybrid protein inhib-
ited the formation of lung and/or lymphatic metastasis
by human ovarian carcinoma and choriocarcinoma
cells. The hybrid protein was much more effective than
uPA-(1-134)-peptide, UTI-(78-136)-peptide, or UTI.
That concludes that this approach extends the possibili-
ty of applying recombinant protein for therapeutic use in
inhibition of human tumor cell metastasis [38-40].
Conclusion
The function of cysteine peptidases and their inhibitors
in genital and breast cancer is not yet well known, but
many researches suggest that they play a main role in
carcinogenesis and metastasis. Some investigators
point out that cysteine proteinases can be used as an
independent factor for prediction of death rates in
patients with breast cancer. Its also important to clear
out that this can be used as an observation tool during
and after therapy. The levels of cysteine peptidases and
their inhibitors can be helpful in identifying patients
with lymph node negative breast cancer, who will not
benefit from systemic adjuvant therapy. Proteinase
inhibitors may also be useful in inhibition of human
tumor cell metastasis especially in genital tumors. 
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